0001628280-26-028901
SEC filingAlignment Healthcare grew revenue 33% and achieved net income profitability driven by 31% membership growth and improved MBR management.
For the three months ended March 31, 2026, Alignment Healthcare delivered strong financial results compared to the same period in 2025. Total revenue increased 33.3% to $1,235.2 million from $926.9 million, driven primarily by a 30.9% growth in health plan membership and higher per-member revenue from increased CMS benchmark rates and Part D subsidies. Earned premiums, which constitute 99.3% of revenue, rose 33.6% to $1,226.6 million.
Medical expenses increased 32.9% to $1,090.7 million, slightly below revenue growth, resulting in a 20-basis-point improvement in the medical benefits ratio (MBR) to 88.2% from 88.4%. This improvement reflects the company's clinical model effectiveness in managing costs even as new members typically join with higher MBRs. Selling, general, and administrative expenses grew 16.7% to $121.1 million but declined as a percentage of revenue from 11.2% to 9.8%, demonstrating economies of scale.
The operating income turned positive to $15.5 million from a loss of $5.4 million in the prior year, a swing of $20.9 million. Net income attributable to Alignment Healthcare was $11.4 million, compared to a net loss of $9.1 million. Adjusted EBITDA, a key non-GAAP metric, increased 87.6% to $37.9 million, reflecting improved underlying profitability.
Cash flow from operations was $128.7 million, a substantial increase from $16.6 million, due to higher net income and favorable working capital changes including timing of medical expense payables. The company ended the quarter with $726.3 million in cash, cash equivalents, and short-term investments.
Alignment Healthcare operates as a single business segment focused on Medicare Advantage plans. The company offers plans in 45 markets across five states, with approximately 8.4 million Medicare-eligible seniors in its current footprint. Membership growth of 30.9% was achieved through both market share gains in existing markets and expansion into new markets. The company noted it holds only 6% market share in its markets, indicating significant room for growth.
There is no detailed segment-level financial breakdown in the MD&A; however, the discussion highlights that the company's clinical model drives superior unit economics, with returning members showing lower MBRs over time. The mix of new versus returning members can cause MBR fluctuations, but the overall trend is improving.
Management's outlook emphasizes continued investment in the proprietary AVA technology platform and Care Anywhere clinical model to drive member growth and cost control. The company plans to expand into new markets and pursue strategic acquisitions, particularly healthcare delivery groups and provider-sponsored Medicare Advantage plans. Key growth drivers include capitalizing on existing market opportunities (10–30% market share in mature markets) and replicating the model in new geographies.
The company expects seasonality with most member growth occurring in Q1 and higher medical costs in colder months. Investments in sales and marketing are weighted to the second half of the year. The recent $200 million revolving credit facility provides additional liquidity for acquisitions and working capital. Management believes current liquidity is sufficient for at least the next 12 months.
No specific numerical guidance was provided for future periods, but the strategic priorities suggest continued momentum in membership growth and profitability improvement, supported by the company's focus on achieving 4-star or better CMS ratings (100% of members in such plans) and managing medical costs proactively.
As of March 31, 2026, the company held $705.6M in cash and cash equivalents, up from $575.8M at year-end 2025. Current investments (U.S. Treasury bills) totaled $20.7M. The debt position consisted of $330.0M aggregate principal of 4.25% Convertible Senior Notes due 2029, net of unamortized issuance costs of $6.4M, resulting in a carrying value of $323.6M. Shareholders' equity was $206.9M. The current ratio (current assets/current liabilities) is 1.58x, indicating adequate short-term liquidity. A new $200M senior secured revolving credit facility was entered on February 26, 2026, but remains undrawn; it matures in 2029 and includes financial covenants.
No material purchase commitments or contractual obligations were disclosed in the notes. The company is subject to regulatory capital requirements (RBC and TNE) and is in compliance as of March 31, 2026. A risk adjustment data validation (RADV) audit for payment year 2019 is ongoing, but no material liability has been accrued.
No share repurchases or dividends were declared or paid during the quarter. Capital expenditures totaled $7.4M (0.6% of revenues), primarily for software and equipment. Debt activity was limited to the amortization of issuance costs and the new credit facility setup; no borrowings were made. The company does not have a formal buyback program.
The company operates as a single reportable segment: providing Medicare Advantage plans. The CODM evaluates performance using consolidated net income. Revenues for Q1 2026 were $1.235B, up 33% from $0.927B in Q1 2025. No geographic revenue breakdown is provided in the notes; operations are concentrated in California, North Carolina, Nevada, Arizona, and Texas.